AML with an immunophenotypic signature similar to that of multipotent progenitors (MPPs) is enriched in mutations in epigenetic modifiers, spliceosomes, and myeloid transcription factors, mainly RUNX1 and ETV6. This evidence concerns the gene ETV6 and acute myeloid leukemia.